Regenxbio price target raised to $39 from $34 at Baird

Baird raised the firm’s price target on Regenxbio to $39 from $34 and keeps an Outperform rating on the shares. The firm noted the first patient at dose level 2 of RGX-202 showed 76% expression and solid CK reduction, and so they walk away with a higher degree of confidence that the higher dose can improve the consistency of response to treatment in a larger trial, without a meaningful increase in safety risk.